{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:10:07Z","timestamp":1770934207396,"version":"3.50.1"},"reference-count":80,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1517\/14740338.2014.951325","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T01:26:05Z","timestamp":1408497965000},"page":"1733-1742","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium"],"prefix":"10.1517","volume":"13","author":[{"given":"Salvatore","family":"Gentile","sequence":"first","affiliation":[{"name":"Mental Health Center Cava de' Tirreni-Vietri sul Mare-","place":["Italy"]},{"name":"University of Naples, Medical School \u201cFederico II\u201d, Department of Neurosciences","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,8,19]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.14.9.522"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.740"},{"key":"e_1_3_1_5_1","first-page":"55","article-title":"Schizophrenia: overview","volume":"3","author":"Bunney WE","year":"1995","unstructured":"Bunney WE, Meltzer HY. Schizophrenia: overview. Clin Neurosci 1995;3:55-6","journal-title":"Clin Neurosci"},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/S0007125000292714","article-title":"The epidemiology of early schizophrenia. Influence of age and gender on onset and early course","volume":"23","author":"Hafner H","year":"1994","unstructured":"Hafner H, Maurer K, Loffler W, et al. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry 1994;23(Suppl):29-38","journal-title":"Br J Psychiatry"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.79"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1225529"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291707002280"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2007.05.012"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.1.69"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70334-5"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00142-6"},{"key":"e_1_3_1_14_1","unstructured":"U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1 2000 to July 1 2004 (NC-EST2004-02) Source: Population Division U.S. Census Bureau Release Date: June 9 2005. Available from: http:\/\/www.census.gov\/popest\/national\/asrh\/ [Accessed 15 June 2014]"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7085"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721050-00002"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246217.34024.53"},{"issue":"2","key":"e_1_3_1_19_1","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer HY","year":"1992","unstructured":"Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1992;21(2 Suppl):S106-15","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_1_20_1","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implication for atypical antipsychotic action","volume":"25","author":"Kapur S","year":"2000","unstructured":"Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implication for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000336"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D485"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e3283413451"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01532-7"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05830.x"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.2.212.33145"},{"key":"e_1_3_1_28_1","unstructured":"DrugLib.com. Abilify (Aripiprazole) - description and clinical pharmacology. Available from: http:\/\/www.druglib.com\/druginfo\/abilify\/description_pharmacology\/ [Accessed: 18 April 2014]"},{"key":"e_1_3_1_29_1","unstructured":"emc. Abilify 7.5 mg\/ml solution for injection (intramuscular). Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/20802\/SPC\/Abilify+7.5+mg+ml+solution+for+injection+(intramuscular)\/ [Accessed 30 April 2014]"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.GOAG.043013"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S32972"},{"key":"e_1_3_1_32_1","unstructured":"Abilify. Full prescribing information. Available from: http:\/\/www.otsuka-us.com\/Documents\/Abilify.PI.pdf [Accessed 2 May 2014]"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020216"},{"key":"e_1_3_1_34_1","unstructured":"Medscape Multispeciality. FDA approves aripiprazole to treat irritability in autistic children. Available from: http:\/\/www.medscape.com\/viewarticle\/713006 [Accessed 18 April 2014]"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216110-00008"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003651"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1003"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629040-00002"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00589.x"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S4167"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001494"},{"key":"e_1_3_1_42_1","volume-title":"Product information. Abilify (aripiprazole)","year":"2003","unstructured":"Product information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ; 2003"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00316.x"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-008-0022-9"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G507"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218c400"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318222bc65"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d27c7d"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1312591"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.566547"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000079"},{"issue":"1","key":"e_1_3_1_52_1","first-page":"1","article-title":"The use of aripiprazole during pregnancy: a case report","volume":"28","author":"Derganc M","year":"2013","unstructured":"Derganc M, Savs AP. The use of aripiprazole during pregnancy: a case report. Eur Psychiatry 2013;28(Suppl 1):1","journal-title":"Eur Psychiatry"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.01.685"},{"key":"e_1_3_1_54_1","unstructured":"Bellet F Beyens MN Bernard N et al. Pregnancy outcome in women exposed to aripiprazole during the embryonic period: a prospective multicentric cohort study. Poster presented at the VIIIeme Congres de Physiologie de Pharmacologie et de Therapeutique; 22 \u2013 24 April 2013; Angers (France). p.26-05 Available from: http:\/\/www.atout-org.com\/p2t2013\/abstract_display!fr!!!!00af00da-8e7a-1030-b866-9251dd645b9d!2f878808-bcdf-1030-b866-9251dd645b9d [Accessed 17 April 2014]"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-008-0044-3"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318295fe12"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003062"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094788"},{"key":"e_1_3_1_59_1","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000000171","article-title":"Perinatal use of aripiprazole. Plasma Levels, placental transfer, and child outcome in 3 new cases","author":"Windhager E","year":"2014","unstructured":"Windhager E, Kim SW, Saria A, et al. Perinatal use of aripiprazole. Plasma Levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol 2014. [Epub ahead of print]","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707007602"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7367"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn107"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326100-00005"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0421"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111886"},{"key":"e_1_3_1_66_1","volume-title":"Medication and mother\u2019s milk","author":"Hale T","year":"2012","unstructured":"Hale T. Medication and mother\u2019s milk. 16th edition. Hale Publishing, Amarillo, TX; 2012","edition":"16"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_3_1_68_1","unstructured":"Coventry & Warwickshire. Area Prescribing Committee. Drug Positioning Statement. Abilify Maintena\u00ae. Available from: http:\/\/www.google.it\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=19&ved=0CGEQFjAIOAo&url=http%3A%2F%2Fwww.coventrywarksapc.nhs.uk%2Fmf.ashx%3FID%3Dbf67bf8b-999b-499b-807b-56a3dfb82dfa&ei=_LqdU_SELObE0QXq5YGYCQ&usg=AFQjCNFSP5Pys-glmhpU-dd1lsJ4Ggergg [Accessed 19 July 2014]"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)88746-9"},{"key":"e_1_3_1_70_1","unstructured":"Bristol-Myers Squibb. CN138-001: A multicenter randomized double-blind placebo controlled study of three fixed doses of aripiprazole in the treatment of patients with acute schizophrenia [online]. 2001. Dated 27 July 2001. Available from: http:\/\/ctr.bms.com\/pdf\/CN138001.pdf [Accessed 26 July 2014]"},{"key":"e_1_3_1_71_1","unstructured":"Bristol-Myers Squibb. CN138-002 (26-52 week): A multicenter randomized double-blind safety and tolerability study of flexible doses of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online]. 2004a. Dated 1 December 2004 Available from: http:\/\/ctr.bms.com\/pdf\/CN138002.pdf [Accessed 17 July 2014]"},{"key":"e_1_3_1_72_1","unstructured":"Bristol-Myers Squibb. CN138-010: a multicenter randomized double-blind placebo controlled study of aripiprazole in the maintenance treatment of patients with bipolar disorder [online]. 2003a. Dated17 December 2003 Available from: http:\/ctr.bms.com\/pdf\/CN138010.pdf [Accessed 19 July 2014]"},{"key":"e_1_3_1_73_1","unstructured":"Bristol-Myers Squibb. CN138-087: A prospective multicenter open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practices [online]. 2004d. Dated 29 April 2004 Available from: http:\/\/ctr.bms.com\/pdf\/CN138087.pdf [Accessed 27 July 2014]"},{"key":"e_1_3_1_74_1","unstructured":"Berman R Fava M Baker RA et al. Metabolic effects of aripiprazole adjunctive therapy in major depressive disorder subpopulations (Studies CN138\u2013139 and CN138\u2013163). Presented at the Annual Meeting of American College of Neuropsychopharmacology; Boca Raton Florida USA; 2007a"},{"key":"e_1_3_1_75_1","unstructured":"Berman RM Kaplita S McQuade RD et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive Disorder (CN138\u2013164). Presented at the Annual Meeting of the American Psychiatric Association; Washington DC USA; 2008"},{"key":"e_1_3_1_76_1","unstructured":"Bristol-Myers Squibb. A multicenter double-blind randomized placebo-controlled flexible-dosed parallel-group study of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder. Dated 2006-2008 Available from: http:\/\/ctr.bms.com\/pdf\/CN138178.pdf [Accessed 30 July 2014]"},{"issue":"1","key":"e_1_3_1_77_1","first-page":"S129","article-title":"Aripiprazole is a high affinity partial agonist at human dopamine D2 receptors","volume":"3","author":"Burris KD","year":"2000","unstructured":"Burris KD, Molski TF, Ryan E, et al. Aripiprazole is a high affinity partial agonist at human dopamine D2 receptors. Int J Neuropsychopharmacol 2000;3(Suppl 1):S129","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_1_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0621-y"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1517\/eoid.12.4.655.23750"},{"key":"e_1_3_1_81_1","unstructured":"DrugLib.com. Drug Information Portal. Active ingredient: Aripiprazole - Basic Profile\/ Key Facts [homepage on the Internet]. Available from: http:\/\/www.druglib.com\/activeingredient\/aripiprazole\/ [Accessed 11 April 2014]"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00099-2"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.2014.951325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:08:06Z","timestamp":1770930486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.2014.951325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,19]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1517\/14740338.2014.951325"],"URL":"https:\/\/doi.org\/10.1517\/14740338.2014.951325","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}